John V. Heymach

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (47)

Supp Table 5. Flatiron Health-Foundation Medicine Clinicogenomic Database (FH-FMI CGDB) cohort characteristics, overall and stratified by treatment with chemotherapy along (Chemo), immune checkpoint inhibitor monotherapy (ICI), or combination ICI with chemotherapy (ICI-chemo)

Year:

2025

A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain metastases prior to starting KRAS G12Ci; C) Survival outcomes according to PD-L1 status (TPS: tumor proportion score); D) survival outcomes in patients with or without prior immune checkpoint inhibitor therapy.

Year:

2025

A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for all patients evaluable for these co-alterations; survival outcomes according to ALK, ROS1, NTRK1-3 co-mutation status in C) all mutation-evaluable patients, and D) limiting the analysis to the KSC WT population.

Year:

2025

Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors in the overall study cohort.

Year:

2025

A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NGS panel providing coverage for all 3 genes were included in this analysis.

Year:

2025

Genomic summary metrics and HLA features of patients with long-term response (LTR), short-term response (STR), and progressive disease (PD) among patients with next-generation sequencing by MSK-IMPACT.

Year:

2025

Purpose: First-line treatment options for MET exon 14 skipping–mutant metastatic non–small cell lung cancer vary because of differences in drug approvals and clinical experience. This study investigates factors influencing outcomes with first-line MET tyrosine kinase inhibitors (TKI) versus immune checkpoint inhibitors (ICI) ± chemotherapy. Experimental Design: Clinicopathologic data were collected from patients with metastatic MET exon 14 skipping–mutant non–small cell lung cancer treated with first-line MET TKI or ICI ± chemotherapy at five centers. Primary endpoints were real-world progression-free survival (rwPFS) and overall survival (OS) to first-line MET TKI versus ICI ± chemotherapy. Subgroup analyses by clinical and tumor characteristics were performed. Results: Among 158 patients, 80 received MET TKI and 78 received ICI ± chemotherapy as first-line treatment. Baseline clinicopathologic features were balanced except for a higher proportion of patients with a history of smoking in the ICI ± chemotherapy group ( P = 0.03). With a median follow-up of 37.9 months, no difference was observed in rwPFS (HR, 0.85; P = 0.4) or OS (HR, 0.97; P = 0.9) with first-line MET TKI versus ICI ± chemotherapy. In subgroup analyses, first-line ICI ± chemotherapy improved rwPFS in PD-L1 ≥80% (HR, 0.50; P = 0.03), whereas MET TKI improved rwPFS (HR, 0.40; P = 0.005) and OS (HR, 0.49; P = 0.03) in PD-L1 P = 0.02) and OS (HR, 0.36; P = 0.03) in brain metastases and rwPFS (HR, 0.55; P = 0.01) in bone metastases. No significant differences were observed in the incidence of high-grade toxicity ( P = 0.9) or rates of permanent treatment discontinuation ( P = 0.2) between first-line MET TKI and ICI ± chemotherapy. Conclusions: First-line MET TKI improved outcomes in PD-L1

Year:

2025

Purpose: Patients with non–small cell lung cancer harboring EGFR mutations typically have significant clinical benefits from EGFR tyrosine kinase inhibitors (TKI) such as osimertinib. However, a residual population of drug-tolerant persister cells (DTPC) inevitably remains, which ultimately gives rise to fully drug-resistant cells (DRC). This study evaluates the activity of EGFR chimeric antigen receptor (CAR)–based therapies in this context. Experimental Design: We developed EGFR CAR T and CAR NK cells and evaluated their antitumor activity against parental cells, DTPC, and DRC in vitro and in vivo . We investigated the mechanisms regulating the sensitivity of DTPC and DRC to CAR T or CAR NK cells, including NK-activating ligands, TGF-β signaling, and EGFR surface levels. Additionally, we developed strategies that included galunisertib treatment and the expression of a dominant-negative TGF-β receptor II in CAR NK cells. Results: DTPC demonstrated increased sensitivity to both EGFR CAR T and CAR NK cells. DRC were relatively resistant to CAR T cells but more sensitive to CAR NK cells. DRC and DTPC had higher levels of natural cytotoxicity triggering receptor-3 and NKG2D ligands, which enhance the effectiveness of CAR NK cells. Elevated TGF-β levels in DRC impaired CAR function, but this was reversed by coexpression of galunisertib or dominant-negative TGF-β receptor II in CAR NK cells. Continued TKI treatment increased EGFR expression on DRC, possibly contributing to the improved killing activity seen with TKI/CAR combinations compared with CAR alone in TKI-resistant cells. Conclusions: EGFR-directed cellular therapies, particularly EGFR CAR NK cells, demonstrate activity against EGFR-mutant DTPC and DRC in vitro and in vivo , with enhanced activity observed when combined with EGFR TKI or TGF-β pathway blockade.

Year:

2025

Purpose: KRAS inhibitors are revolutionizing the treatment of non–small cell lung cancer (NSCLC), but clinico-genomic determinants of treatment efficacy warrant continued exploration. Experimental Design: Patients with advanced KRAS G12C -mutant NSCLC treated with adagrasib [KRYSTAL-1 (NCT03785249)] were included in the analysis. Pretreatment next-generation sequencing data were collected per protocol. HTG EdgeSeq Transcriptome Panel was used for gene expression profiling. Clinical endpoints included objective response, progression-free survival (PFS), and overall survival (OS). KRAS G12C -mutant NSCLC cell lines and xenograft models were used for sensitivity analyses and combination drug screens. Results: KEAP1 MUT and STK11 MUT were associated with shorter survival to adagrasib [ KEAP1 : PFS 4.1 vs. 9.9 months, HR 2.7, P P STK11 : PFS 4.2 vs. 11.0 months, HR 2.2, P P KEAP1 WT / STK11 WT status identified adagrasib-treated patients with significantly longer PFS (16.9 months) and OS (NR). Preclinical analyses further validate the association between KEAP1 loss of function and adagrasib resistance. Adagrasib and mTOR inhibitor combinations produced higher treatment efficacy in NSCLC models harboring STK11 and KEAP1 co-mutations. NRF2 HIGH signaling was associated with shorter survival to adagrasib (PFS: 4.2 vs. 8.4 months, HR 2.0, P = 0.02; OS: 6.5 vs. 19.0 months, HR 2.8, P KEAP1 WT NSCLC. KEAP1 WT / STK11 WT /NRF2 LOW status identified patients—32%—with longer survival to adagrasib (PFS 12.0 vs. 4.2 months, HR 0.2, P P Conclusions: KEAP1 , STK11 , and NRF2 status define patients with KRAS G12C -mutant NSCLC with markedly distinct outcomes to adagrasib. These results further support the use of genomic features—mutational and nonmutational—for the treatment selection of patients with KRAS G12C -mutant NSCLC.

Year:

2025

Supplementary Figure S7. Clinical outcomes to adagrasib monotherapy according to NRF2 score and STK11 co-mutation status in KEAP1 WT / KRAS G12C -mutant NSCLC patients.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (89)

Alessandro Di Federico

University of Bologna

ITALY
View details

Jennifer W Carlisle

Winship Cancer Institute of Emory University

UNITED STATES
View details

Xiuning Le

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Mark Awad

Chief, Thoracic Oncology Service

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

David Gerber

Professor of Internal Medicine (Hematology-Oncology) and Clinical Sciences

University of Texas Southwestern Medical Center

UNITED STATES
View details

Jianjun Zhang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Scott E. Kopetz

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Shunsuke Kondo

Professor

Tokyo Women's Medical University

JAPAN
View details

Neal Akhave

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Christine Bestvina

Assistant Professor

University of Chicago Medicine

UNITED STATES
View details

Sandip Patel

Associate Professor

Moores Cancer Center, UC San Diego Health

UNITED STATES
View details

Marina Garassino

Prof

Università degli Studi di Torino

ITALY
View details

Heath Skinner

Professor & Chair

University of Pittsburgh

UNITED STATES
View details

Mark Davis

Howard Hughes Medical Institute

UNITED STATES
View details

Jacobi Hines

Assistant Professor

Northwestern Medicine

UNITED STATES
View details

Steven Frank

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ajay Sheshadri

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Lauren A. Byers

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Martin Edelman

Physician and Chair

Fox Chase Cancer Center

UNITED STATES
View details

Alfredo Addeo

University Hospital of Geneva

SWITZERLAND
View details

Jeffrey N. Myers

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Curtis R. Pickering

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Qi Wang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Samera Hamad

Assistant Professor

Cooper Medical School of Rowan University

UNITED STATES
View details

Marjorie Zauderer

Section Chief, Hematology & Medical Oncology

New York Medical College

UNITED STATES
View details

Michael A. Curran

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yu Qian

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Mizuki Nishino

King’s College London

UNITED STATES
View details

Petros Christopoulos

-

GERMANY
View details

Phillip Pifer

Assistant Professor

West Virginia University Hospitals

UNITED STATES
View details

Ken Lau

Associate Professor

Vanderbilt University School of Medicine

UNITED STATES
View details

Charles Rudin

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Amy L Cummings

UCLA School of Medicine

UNITED STATES
View details

Mehmet Altan

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Andrew Futreal

Chair and Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Giorgio V Scagliotti

Chair

University of Turin

ITALY
View details

james hicks

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Deborah Schrag

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Mingjia Li

Assistant Professor

Ohio State University

UNITED STATES
View details

Hai Tran

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Bernard E. Weissman

University of North Carolina at Chapel Hill School of Medicine

UNITED STATES
View details

Vlad Sandulache

Associate Professor

Baylor College of Medicine

UNITED STATES
View details

Renata Ferrarotto

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Samir M. Hanash

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Collin Blakely

Assistant Professor

UCSF Medical Center

UNITED STATES
View details

Bin Liu

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Matthias Scheffler

University Hospital Bonn

GERMANY
View details

Chao Cheng

Associate Professor

Baylor College of Medicine

UNITED STATES
View details

J. Jack Lee

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Michael Frumovitz

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Matthew D. Hellmann

Weill Cornell Medical College

UNITED STATES
View details

Jing Wang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Heather Wakelee

Professor

Stanford University

UNITED STATES
View details

Beth M. Beadle

Professor

Stanford University

UNITED STATES
View details

Natalie Vokes

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

LI SHEN

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Francesco Gelsomino

ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA

ITALY
View details

Anna Obenauf

Group leader

Research Institute of Molecular Pathology

AUSTRIA
View details

Mara B. Antonoff

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Andrea De Giglio

University of Bologna

ITALY
View details

Cara Haymaker

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Seyed Javad Moghaddam

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Alexandre Reuben

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Rafael Irizarry

Professor and Chair

Harvard University

UNITED STATES
View details

Simon Heeke

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yukina Shirai

Juntendo University

JAPAN
View details

Muhammad Furqan

Professor

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Ying Ni

Assistant Professor

Case Western Reserve University

UNITED STATES
View details

Catherine Shu

Columbia University Irving Medical Center

UNITED STATES
View details

Ferdinandos Skoulidis

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Albrecht Stenzinger

-

GERMANY
View details

Edwin J. Ostrin

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ken Chen

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Marcelo Negrao

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Don L. Gibbons

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Humam Kadara

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Dwight H. Owen

Ohio State University

UNITED STATES
View details

Jia Wu

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

YASIR ELAMIN

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Tao Wang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Chad Vanderbilt

Associate Attending Pathologist

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Linghua Wang

Executive Director & Head

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Marcello Tiseo

University of Parma

ITALY
View details

ENRIQUETA FELIP

Head Thoracic Oncology Unit (After Competitive Exam)

Hospital Universitari Vall d'Hebron

SPAIN
View details

Gilberto Lopes

Associate Professor

Sylvester Comprehensive Cancer Center

UNITED STATES
View details

Sonia Patel

Life Science Research Professional

Stanford University School of Medicine

UNITED STATES
View details

Abdullah Osman

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details